메뉴 건너뛰기




Volumn 12, Issue 2, 2013, Pages 99-107

Future perspectives on the treatment of cognitive deficits and negative symptoms in schizophrenia

Author keywords

cognition; drug development; negative symptoms; neurodevelopment; neuroplasticity; Schizophrenia

Indexed keywords

ACETYLSALICYLIC ACID; AMPHETAMINE; ANTIDEPRESSANT AGENT; ANTIOXIDANT; BITOPERTIN; BRAIN DERIVED NEUROTROPHIC FACTOR; C REACTIVE PROTEIN; CLOZAPINE; CYANOCOBALAMIN; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSERINE; DEXTRO AMINO ACID OXIDASE; DOPAMINE 1 RECEPTOR; FISH OIL; FOLIC ACID; GLUTAMATE DECARBOXYLASE 67; INTERLEUKIN 6; MINOCYCLINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PSYCHEDELIC AGENT; SEROTONIN UPTAKE INHIBITOR; TOLCAPONE;

EID: 84878546029     PISSN: 17238617     EISSN: 20515545     Source Type: Journal    
DOI: 10.1002/wps.20026     Document Type: Review
Times cited : (27)

References (121)
  • 2
    • 33750625280 scopus 로고    scopus 로고
    • Pharmacological treatment of primary negative symptoms in schizophrenia: A systematic review
    • Murphy BP, Chung YC, Park TW, et al. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res 2006; 88: 5-25.
    • (2006) Schizophr Res , vol.88 , pp. 5-25
    • Murphy, B.P.1    Chung, Y.C.2    Park, T.W.3
  • 3
    • 68449086236 scopus 로고    scopus 로고
    • Common polygenic variation contributes to risk of schizophrenia and bipolar disorder
    • International Schizophrenia Consortium
    • International Schizophrenia Consortium, Purcell SM, Wray NR, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009; 460: 748-52.
    • (2009) Nature , vol.460 , pp. 748-752
    • Purcell, S.M.1    Wray, N.R.2
  • 4
    • 54149094913 scopus 로고    scopus 로고
    • Genetic research in schizophrenia: New tools and future perspectives
    • Bertram L,. Genetic research in schizophrenia: new tools and future perspectives. Schizophr Bull 2008; 34: 806-12.
    • (2008) Schizophr Bull , vol.34 , pp. 806-812
    • Bertram, L.1
  • 5
    • 84867743306 scopus 로고    scopus 로고
    • Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users
    • Di Forti M, Iyegbe C, Sallis H, et al. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry 2012; 72: 811-6.
    • (2012) Biol Psychiatry , vol.72 , pp. 811-816
    • Di Forti, M.1    Iyegbe, C.2    Sallis, H.3
  • 6
    • 0028316414 scopus 로고
    • Cannabis abuse and the course of recent-onset schizophrenic disorders
    • Linszen DH, Dingemans PM, Lenior ME,. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994; 51: 273-9.
    • (1994) Arch Gen Psychiatry , vol.51 , pp. 273-279
    • Linszen, D.H.1    Dingemans, P.M.2    Lenior, M.E.3
  • 7
    • 84555220553 scopus 로고    scopus 로고
    • Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: A pathway to smaller hippocampal volume
    • Mondelli V, Cattaneo A, Belvederi Murri M, et al. Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. J Clin Psychiatry 2011; 72: 1677-84.
    • (2011) J Clin Psychiatry , vol.72 , pp. 1677-1684
    • Mondelli, V.1    Cattaneo, A.2    Belvederi Murri, M.3
  • 8
    • 68049121851 scopus 로고    scopus 로고
    • The novel oxidative stress marker thioredoxin is increased in first-episode schizophrenic patients
    • Zhang XY, Chen da C, Xiu MH, et al. The novel oxidative stress marker thioredoxin is increased in first-episode schizophrenic patients. Schizophr Res 2009; 113: 151-7.
    • (2009) Schizophr Res , vol.113 , pp. 151-157
    • Zhang, X.Y.1    Chen Da, C.2    Xiu, M.H.3
  • 9
    • 84860835844 scopus 로고    scopus 로고
    • Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes
    • Martinez-Cengotitabengoa M, Mac-Dowell KS, Leza JC, et al. Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes. Schizophr Res 2012; 137: 66-72.
    • (2012) Schizophr Res , vol.137 , pp. 66-72
    • Martinez-Cengotitabengoa, M.1    Mac-Dowell, K.S.2    Leza, J.C.3
  • 10
    • 78651312636 scopus 로고    scopus 로고
    • Brain anatomical abnormalities in high-risk individuals, first-episode, and chronic schizophrenia: An activation likelihood estimation meta-analysis of illness progression
    • Chan RC, Di X, McAlonan GM, et al. Brain anatomical abnormalities in high-risk individuals, first-episode, and chronic schizophrenia: an activation likelihood estimation meta-analysis of illness progression. Schizophr Bull 2011; 37: 177-88.
    • (2011) Schizophr Bull , vol.37 , pp. 177-188
    • Chan, R.C.1    Di, X.2    McAlonan, G.M.3
  • 12
    • 0033399541 scopus 로고    scopus 로고
    • Dopamine as the wind of the psychotic fire: New evidence from brain imaging studies
    • Laruelle M, Abi-Dargham A,. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol 1999; 13: 358-71.
    • (1999) J Psychopharmacol , vol.13 , pp. 358-371
    • Laruelle, M.1    Abi-Dargham, A.2
  • 13
    • 0034843738 scopus 로고    scopus 로고
    • The emerging role of glutamate in the pathophysiology and treatment of schizophrenia
    • Goff DC, Coyle JT,. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001; 158: 1367-77.
    • (2001) Am J Psychiatry , vol.158 , pp. 1367-1377
    • Goff, D.C.1    Coyle, J.T.2
  • 14
    • 33845794324 scopus 로고    scopus 로고
    • Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks
    • Bartos M, Vida I, Jonas P,. Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks. Nature Rev Neurosci 2007; 8: 45-56.
    • (2007) Nature Rev Neurosci , vol.8 , pp. 45-56
    • Bartos, M.1    Vida, I.2    Jonas, P.3
  • 15
    • 24344441586 scopus 로고    scopus 로고
    • Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: A systematic review
    • Marshall M, Lewis S, Lockwood A, et al. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 2005; 62: 975-83.
    • (2005) Arch Gen Psychiatry , vol.62 , pp. 975-983
    • Marshall, M.1    Lewis, S.2    Lockwood, A.3
  • 16
    • 65649137337 scopus 로고    scopus 로고
    • Volume and neuron number of the lateral geniculate nucleus in schizophrenia and mood disorders
    • Dorph-Petersen KA, Caric D, Saghafi R, et al. Volume and neuron number of the lateral geniculate nucleus in schizophrenia and mood disorders. Acta Neuropathol 2009; 117: 369-84.
    • (2009) Acta Neuropathol , vol.117 , pp. 369-384
    • Dorph-Petersen, K.A.1    Caric, D.2    Saghafi, R.3
  • 17
    • 27744569450 scopus 로고    scopus 로고
    • The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: A comparison of haloperidol and olanzapine in macaque monkeys
    • Dorph-Petersen KA, Pierri JN, Perel JM, et al. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology 2005; 30: 1649-61.
    • (2005) Neuropsychopharmacology , vol.30 , pp. 1649-1661
    • Dorph-Petersen, K.A.1    Pierri, J.N.2    Perel, J.M.3
  • 18
    • 79955474356 scopus 로고    scopus 로고
    • Effect of chronic antipsychotic treatment on brain structure: A serial magnetic resonance imaging study with ex vivo and postmortem confirmation
    • Vernon AC, Natesan S, Modo M, et al. Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation. Biol Psychiatry 2011; 69: 936-44.
    • (2011) Biol Psychiatry , vol.69 , pp. 936-944
    • Vernon, A.C.1    Natesan, S.2    Modo, M.3
  • 19
    • 0034678029 scopus 로고    scopus 로고
    • Reversal of working memory deficits by short-term dopamine D1 receptor stimulation
    • Castner SA, Williams GV, Goldman-Rakic PS,. Reversal of working memory deficits by short-term dopamine D1 receptor stimulation. Science 2000; 287: 2020-2.
    • (2000) Science , vol.287 , pp. 2020-2022
    • Castner, S.A.1    Williams, G.V.2    Goldman-Rakic, P.S.3
  • 20
    • 3543093977 scopus 로고    scopus 로고
    • Serologic evidence of prenatal influenza in the etiology of schizophrenia
    • Brown AS, Begg MD, Gravenstein S, et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry 2004; 61: 774-80.
    • (2004) Arch Gen Psychiatry , vol.61 , pp. 774-780
    • Brown, A.S.1    Begg, M.D.2    Gravenstein, S.3
  • 21
    • 36049009089 scopus 로고    scopus 로고
    • Obstetric conditions and risk of first admission with schizophrenia: A Danish national register based study
    • Byrne M, Agerbo E, Bennedsen B, et al. Obstetric conditions and risk of first admission with schizophrenia: a Danish national register based study. Schizophr Res 2007; 97: 51-9.
    • (2007) Schizophr Res , vol.97 , pp. 51-59
    • Byrne, M.1    Agerbo, E.2    Bennedsen, B.3
  • 22
    • 2442593823 scopus 로고    scopus 로고
    • Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring
    • Brown AS, Hooton J, Schaefer CA, et al. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am J Psychiatry 2004; 161: 889-95.
    • (2004) Am J Psychiatry , vol.161 , pp. 889-895
    • Brown, A.S.1    Hooton, J.2    Schaefer, C.A.3
  • 23
    • 73949137920 scopus 로고    scopus 로고
    • Schizophrenia susceptibility genes directly implicated in the life cycles of pathogens: Cytomegalovirus, influenza, herpes simplex, rubella, and Toxoplasma gondii
    • Carter CJ,. Schizophrenia susceptibility genes directly implicated in the life cycles of pathogens: cytomegalovirus, influenza, herpes simplex, rubella, and Toxoplasma gondii. Schizophr Bull 2009; 35: 1163-82.
    • (2009) Schizophr Bull , vol.35 , pp. 1163-1182
    • Carter, C.J.1
  • 24
    • 0033588276 scopus 로고    scopus 로고
    • Evidence for activation of microglia in patients with psychiatric illnesses
    • Bayer TA, Buslei R, Havas L, et al. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci Lett 1999; 271: 126-8.
    • (1999) Neurosci Lett , vol.271 , pp. 126-128
    • Bayer, T.A.1    Buslei, R.2    Havas, L.3
  • 25
    • 0033983020 scopus 로고    scopus 로고
    • Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics
    • Radewicz K, Garey LJ, Gentleman SM, et al. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J Neuropathol Exper Neurol 2000; 59: 137-50.
    • (2000) J Neuropathol Exper Neurol , vol.59 , pp. 137-150
    • Radewicz, K.1    Garey, L.J.2    Gentleman, S.M.3
  • 26
    • 53249144430 scopus 로고    scopus 로고
    • Microglia activation in recent-onset schizophrenia: A quantitative (R)-[11C]PK11195 positron emission tomography study
    • van Berckel BN, Bossong MG, Boellaard R, et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry 2008; 64: 820-2.
    • (2008) Biol Psychiatry , vol.64 , pp. 820-822
    • Van Berckel, B.N.1    Bossong, M.G.2    Boellaard, R.3
  • 27
    • 70350724581 scopus 로고    scopus 로고
    • Neuroinflammation in schizophrenia-related psychosis: A PET study
    • Doorduin J, de Vries EF, Willemsen AT, et al. Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med 2009; 50: 1801-7.
    • (2009) J Nucl Med , vol.50 , pp. 1801-1807
    • Doorduin, J.1    De Vries, E.F.2    Willemsen, A.T.3
  • 28
    • 61849179511 scopus 로고    scopus 로고
    • Therapeutic signposts: Using biomarkers to guide better treatment of schizophrenia and other psychotic disorders
    • Banati R, Hickie IB,. Therapeutic signposts: using biomarkers to guide better treatment of schizophrenia and other psychotic disorders. Med J Aust 2009; 190 (Suppl. 4): S26-32.
    • (2009) Med J Aust , vol.190 , Issue.SUPPL. 4
    • Banati, R.1    Hickie, I.B.2
  • 29
    • 80052853015 scopus 로고    scopus 로고
    • Meta-analysis of cytokine alterations in schizophrenia: Clinical status and antipsychotic effects
    • Miller BJ, Buckley P, Seabolt W, et al. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011; 70: 663-71.
    • (2011) Biol Psychiatry , vol.70 , pp. 663-671
    • Miller, B.J.1    Buckley, P.2    Seabolt, W.3
  • 30
    • 67749114055 scopus 로고    scopus 로고
    • Immune involvement in schizophrenia and autism: Etiology, pathology and animal models
    • Patterson PH,. Immune involvement in schizophrenia and autism: etiology, pathology and animal models. Behav Brain Res 2009; 204: 313-21.
    • (2009) Behav Brain Res , vol.204 , pp. 313-321
    • Patterson, P.H.1
  • 31
    • 48249117121 scopus 로고    scopus 로고
    • Maternal immune activation in mice delays myelination and axonal development in the hippocampus of the offspring
    • Makinodan M, Tatsumi K, Manabe T, et al. Maternal immune activation in mice delays myelination and axonal development in the hippocampus of the offspring. J Neurosci Res 2008; 86: 2190-200.
    • (2008) J Neurosci Res , vol.86 , pp. 2190-2200
    • Makinodan, M.1    Tatsumi, K.2    Manabe, T.3
  • 32
    • 84861947641 scopus 로고    scopus 로고
    • Prenatal activation of Toll-like receptors-3 by administration of the viral mimetic poly(I:C) changes synaptic proteins, N-methyl-D-aspartate receptors and neurogenesis markers in offspring
    • Forrest CM, Khalil OS, Pisar M, et al. Prenatal activation of Toll-like receptors-3 by administration of the viral mimetic poly(I:C) changes synaptic proteins, N-methyl-D-aspartate receptors and neurogenesis markers in offspring. Mol Brain 2012; 5: 22.
    • (2012) Mol Brain , vol.5 , pp. 22
    • Forrest, C.M.1    Khalil, O.S.2    Pisar, M.3
  • 33
    • 80051789320 scopus 로고    scopus 로고
    • Microglial activation in a neuroinflammational animal model of schizophrenia - A pilot study
    • Juckel G, Manitz MP, Brune M, et al. Microglial activation in a neuroinflammational animal model of schizophrenia-a pilot study. Schizophr Res 2011; 131: 96-100.
    • (2011) Schizophr Res , vol.131 , pp. 96-100
    • Juckel, G.1    Manitz, M.P.2    Brune, M.3
  • 34
    • 70350721661 scopus 로고    scopus 로고
    • Clozapine administration in adolescence prevents postpubertal emergence of brain structural pathology in an animal model of schizophrenia
    • Piontkewitz Y, Assaf Y, Weiner I,. Clozapine administration in adolescence prevents postpubertal emergence of brain structural pathology in an animal model of schizophrenia. Biol Psychiatry 2009; 66: 1038-46.
    • (2009) Biol Psychiatry , vol.66 , pp. 1038-1046
    • Piontkewitz, Y.1    Assaf, Y.2    Weiner, I.3
  • 35
    • 34249335327 scopus 로고    scopus 로고
    • C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia
    • Dickerson F, Stallings C, Origoni A, et al. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res 2007; 93: 261-5.
    • (2007) Schizophr Res , vol.93 , pp. 261-265
    • Dickerson, F.1    Stallings, C.2    Origoni, A.3
  • 36
    • 33846261538 scopus 로고    scopus 로고
    • Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia
    • Fan X, Pristach C, Liu EY, et al. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res 2007; 149: 267-71.
    • (2007) Psychiatry Res , vol.149 , pp. 267-271
    • Fan, X.1    Pristach, C.2    Liu, E.Y.3
  • 37
    • 83655163937 scopus 로고    scopus 로고
    • C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia
    • Fawzi MH, Fawzi MM, Fawzi MM, et al. C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia. Psychiatry Res 2011; 190: 91-7.
    • (2011) Psychiatry Res , vol.190 , pp. 91-97
    • Fawzi, M.H.1    Fawzi, M.M.2    Fawzi, M.M.3
  • 38
    • 80052437053 scopus 로고    scopus 로고
    • Progressive gray matter loss and changes in cognitive functioning associated with exposure to herpes simplex virus 1 in schizophrenia: A longitudinal study
    • Prasad KM, Eack SM, Goradia D, et al. Progressive gray matter loss and changes in cognitive functioning associated with exposure to herpes simplex virus 1 in schizophrenia: a longitudinal study. Am J Psychiatry 2011; 168: 822-30.
    • (2011) Am J Psychiatry , vol.168 , pp. 822-830
    • Prasad, K.M.1    Eack, S.M.2    Goradia, D.3
  • 39
    • 79955474674 scopus 로고    scopus 로고
    • Serological evidence of exposure to Herpes Simplex Virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample
    • Yolken RH, Torrey EF, Lieberman JA, et al. Serological evidence of exposure to Herpes Simplex Virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample. Schizophr Res 2011; 128: 61-5.
    • (2011) Schizophr Res , vol.128 , pp. 61-65
    • Yolken, R.H.1    Torrey, E.F.2    Lieberman, J.A.3
  • 40
    • 67650652986 scopus 로고    scopus 로고
    • Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex?
    • Behrens MM, Sejnowski TJ,. Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex? Neuropharmacology 2009; 57: 193-200.
    • (2009) Neuropharmacology , vol.57 , pp. 193-200
    • Behrens, M.M.1    Sejnowski, T.J.2
  • 41
    • 67649840212 scopus 로고    scopus 로고
    • The development of neural synchrony reflects late maturation and restructuring of functional networks in humans
    • Uhlhaas PJ, Roux F, Singer W, et al. The development of neural synchrony reflects late maturation and restructuring of functional networks in humans. Proc Natl Acad Sci USA 2009; 106: 9866-71.
    • (2009) Proc Natl Acad Sci USA , vol.106 , pp. 9866-9871
    • Uhlhaas, P.J.1    Roux, F.2    Singer, W.3
  • 42
    • 0344628603 scopus 로고    scopus 로고
    • Overproduction of neutrophil radical oxygen species correlates with negative symptoms in schizophrenic patients: Parallel studies on neutrophil chemotaxis, superoxide production and bactericidal activity
    • Sirota P, Gavrieli R, Wolach B,. Overproduction of neutrophil radical oxygen species correlates with negative symptoms in schizophrenic patients: parallel studies on neutrophil chemotaxis, superoxide production and bactericidal activity. Psychiatry Res 2003; 121: 123-32.
    • (2003) Psychiatry Res , vol.121 , pp. 123-132
    • Sirota, P.1    Gavrieli, R.2    Wolach, B.3
  • 43
    • 33845671189 scopus 로고    scopus 로고
    • Oncostatin M is a neuroprotective cytokine that inhibits excitotoxic injury in vitro and in vivo
    • Weiss TW, Samson AL, Niego B, et al. Oncostatin M is a neuroprotective cytokine that inhibits excitotoxic injury in vitro and in vivo. FASEB Journal 2006; 20: 2369-71.
    • (2006) FASEB Journal , vol.20 , pp. 2369-2371
    • Weiss, T.W.1    Samson, A.L.2    Niego, B.3
  • 44
    • 47249164327 scopus 로고    scopus 로고
    • Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder
    • Beneyto M, Meador-Woodruff JH,. Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology 2008; 33: 2175-86.
    • (2008) Neuropsychopharmacology , vol.33 , pp. 2175-2186
    • Beneyto, M.1    Meador-Woodruff, J.H.2
  • 45
    • 70349774217 scopus 로고    scopus 로고
    • Viral-like brain inflammation during development causes increased seizure susceptibility in adult rats
    • Galic MA, Riazi K, Henderson AK, et al. Viral-like brain inflammation during development causes increased seizure susceptibility in adult rats. Neurobiol Dis 2009; 36: 343-51.
    • (2009) Neurobiol Dis , vol.36 , pp. 343-351
    • Galic, M.A.1    Riazi, K.2    Henderson, A.K.3
  • 46
    • 16844382943 scopus 로고    scopus 로고
    • BDNF in schizophrenia, depression and corresponding animal models
    • Angelucci F, Brene S, Mathe AA,. BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry 2005; 10: 345-52.
    • (2005) Mol Psychiatry , vol.10 , pp. 345-352
    • Angelucci, F.1    Brene, S.2    Mathe, A.A.3
  • 47
    • 77954421126 scopus 로고    scopus 로고
    • The BDNF Val66Met polymorphism impairs NMDA receptor-dependent synaptic plasticity in the hippocampus
    • Ninan I, Bath KG, Dagar K, et al. The BDNF Val66Met polymorphism impairs NMDA receptor-dependent synaptic plasticity in the hippocampus. J Neurosci 2010; 30: 8866-70.
    • (2010) J Neurosci , vol.30 , pp. 8866-8870
    • Ninan, I.1    Bath, K.G.2    Dagar, K.3
  • 48
    • 78650799875 scopus 로고    scopus 로고
    • Hippocampal volumes and the brain-derived neurotrophic factor val66met polymorphism in geriatric major depression
    • Kanellopoulos D, Gunning FM, Morimoto SS, et al. Hippocampal volumes and the brain-derived neurotrophic factor val66met polymorphism in geriatric major depression. Am J Geriatr Psychiatry 2011; 19: 13-22.
    • (2011) Am J Geriatr Psychiatry , vol.19 , pp. 13-22
    • Kanellopoulos, D.1    Gunning, F.M.2    Morimoto, S.S.3
  • 49
    • 69249228582 scopus 로고    scopus 로고
    • Ageing abolishes the effects of fluoxetine on neurogenesis
    • Couillard-Despres S, Wuertinger C, Kandasamy M, et al. Ageing abolishes the effects of fluoxetine on neurogenesis. Mol Psychiatry 2009; 14: 856-64.
    • (2009) Mol Psychiatry , vol.14 , pp. 856-864
    • Couillard-Despres, S.1    Wuertinger, C.2    Kandasamy, M.3
  • 50
    • 38449085832 scopus 로고    scopus 로고
    • Association between brain-derived neurotrophic factor Val66Met gene polymorphism and progressive brain volume changes in schizophrenia
    • Ho BC, Andreasen NC, Dawson JD, et al. Association between brain-derived neurotrophic factor Val66Met gene polymorphism and progressive brain volume changes in schizophrenia. Am J Psychiatry 2007; 164: 1890-9.
    • (2007) Am J Psychiatry , vol.164 , pp. 1890-1899
    • Ho, B.C.1    Andreasen, N.C.2    Dawson, J.D.3
  • 51
    • 77950598371 scopus 로고    scopus 로고
    • Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action
    • Freyberg Z, Ferrando SJ, Javitch JA,. Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am J Psychiatry 2010; 167: 388-96.
    • (2010) Am J Psychiatry , vol.167 , pp. 388-396
    • Freyberg, Z.1    Ferrando, S.J.2    Javitch, J.A.3
  • 52
    • 78649906486 scopus 로고    scopus 로고
    • Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia
    • Balu DT, Coyle JT,. Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia. Neurosci Biobehav Rev 2012; 35: 848-70.
    • (2012) Neurosci Biobehav Rev , vol.35 , pp. 848-870
    • Balu, D.T.1    Coyle, J.T.2
  • 54
    • 84863872722 scopus 로고    scopus 로고
    • Omega-3 supplementation lowers inflammation in healthy middle-aged and older adults: A randomized controlled trial
    • Kiecolt-Glaser JK, Belury MA, Andridge R, et al. Omega-3 supplementation lowers inflammation in healthy middle-aged and older adults: a randomized controlled trial. Brain, Behavior and Immunity 2012; 26: 988-95.
    • (2012) Brain, Behavior and Immunity , vol.26 , pp. 988-995
    • Kiecolt-Glaser, J.K.1    Belury, M.A.2    Andridge, R.3
  • 55
    • 76149102249 scopus 로고    scopus 로고
    • Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: A randomized, placebo-controlled trial
    • Amminger GP, Schafer MR, Papageorgiou K, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010; 67: 146-54.
    • (2010) Arch Gen Psychiatry , vol.67 , pp. 146-154
    • Amminger, G.P.1    Schafer, M.R.2    Papageorgiou, K.3
  • 56
    • 84857885522 scopus 로고    scopus 로고
    • Eicosapentaenoic acid interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled studies
    • Fusar-Poli P, Berger G,. Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies. J Clin Psychopharmacol 2012; 32: 179-85.
    • (2012) J Clin Psychopharmacol , vol.32 , pp. 179-185
    • Fusar-Poli, P.1    Berger, G.2
  • 57
    • 33846620518 scopus 로고    scopus 로고
    • Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial
    • Akhondzadeh S, Tabatabaee M, Amini H, et al. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 2007; 90: 179-85.
    • (2007) Schizophr Res , vol.90 , pp. 179-185
    • Akhondzadeh, S.1    Tabatabaee, M.2    Amini, H.3
  • 58
    • 77955050321 scopus 로고    scopus 로고
    • Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment
    • Muller N, Krause D, Dehning S, et al. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 2010; 121: 118-24.
    • (2010) Schizophr Res , vol.121 , pp. 118-124
    • Muller, N.1    Krause, D.2    Dehning, S.3
  • 59
    • 77952641170 scopus 로고    scopus 로고
    • Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: Results from a randomized, double-blind, placebo-controlled trial
    • Laan W, Grobbee DE, Selten JP, et al. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010; 71: 520-7.
    • (2010) J Clin Psychiatry , vol.71 , pp. 520-527
    • Laan, W.1    Grobbee, D.E.2    Selten, J.P.3
  • 60
    • 84860544826 scopus 로고    scopus 로고
    • Nonsteroidal anti-inflammatory drugs in schizophrenia: Ready for practice or a good start? A meta-analysis
    • Sommer IE, de Witte L, Begemann M, et al. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry 2012; 73: 414-9.
    • (2012) J Clin Psychiatry , vol.73 , pp. 414-419
    • Sommer, I.E.1    De Witte, L.2    Begemann, M.3
  • 61
    • 84864999825 scopus 로고    scopus 로고
    • Minocycline benefits negative symptoms in early schizophrenia: A randomised double-blind placebo-controlled clinical trial in patients on standard treatment
    • Chaudhry IB, Hallak J, Husain N, et al. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol 2012; 26: 1185-93.
    • (2012) J Psychopharmacol , vol.26 , pp. 1185-1193
    • Chaudhry, I.B.1    Hallak, J.2    Husain, N.3
  • 62
    • 79851486421 scopus 로고    scopus 로고
    • 11C-(R)-PK11195 PET imaging of microglial activation and response to minocycline in zymosan-treated rats
    • Converse AK, Larsen EC, Engle JW, et al. 11C-(R)-PK11195 PET imaging of microglial activation and response to minocycline in zymosan-treated rats. J Nucl Med 2011; 52: 257-62.
    • (2011) J Nucl Med , vol.52 , pp. 257-262
    • Converse, A.K.1    Larsen, E.C.2    Engle, J.W.3
  • 63
    • 0035871840 scopus 로고    scopus 로고
    • Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia
    • Tikka T, Fiebich BL, Goldsteins G, et al. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 2001; 21: 2580-8.
    • (2001) J Neurosci , vol.21 , pp. 2580-2588
    • Tikka, T.1    Fiebich, B.L.2    Goldsteins, G.3
  • 64
    • 84864999825 scopus 로고    scopus 로고
    • Minocycline benefits negative symptoms in early schizophrenia: A randomised double-blind placebo-controlled clinical trial in patients on standard treatment
    • Chaudhry IB, Hallak J, Husain N, et al. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol 2012; 26: 1185-93.
    • (2012) J Psychopharmacol , vol.26 , pp. 1185-1193
    • Chaudhry, I.B.1    Hallak, J.2    Husain, N.3
  • 65
    • 77649112679 scopus 로고    scopus 로고
    • A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia
    • Levkovitz Y, Mendlovich S, Riwkes S, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010; 71: 138-49.
    • (2010) J Clin Psychiatry , vol.71 , pp. 138-149
    • Levkovitz, Y.1    Mendlovich, S.2    Riwkes, S.3
  • 66
    • 67650932879 scopus 로고    scopus 로고
    • Redox dysregulation, neurodevelopment, and schizophrenia
    • Do KQ, Cabungcal JH, Frank A, et al. Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol 2009; 19: 220-30.
    • (2009) Curr Opin Neurobiol , vol.19 , pp. 220-230
    • Do, K.Q.1    Cabungcal, J.H.2    Frank, A.3
  • 67
    • 43649090465 scopus 로고    scopus 로고
    • Contribution of cystine-glutamate antiporters to the psychotomimetic effects of phencyclidine
    • Baker DA, Madayag A, Kristiansen LV, et al. Contribution of cystine-glutamate antiporters to the psychotomimetic effects of phencyclidine. Neuropsychopharmacology 2008; 33: 1760-72.
    • (2008) Neuropsychopharmacology , vol.33 , pp. 1760-1772
    • Baker, D.A.1    Madayag, A.2    Kristiansen, L.V.3
  • 68
    • 48749112603 scopus 로고    scopus 로고
    • N-acetyl cysteine as a glutathione precursor for schizophrenia - A double-blind, randomized, placebo-controlled trial
    • Berk M, Copolov D, Dean O, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia - a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008; 64: 361-8.
    • (2008) Biol Psychiatry , vol.64 , pp. 361-368
    • Berk, M.1    Copolov, D.2    Dean, O.3
  • 69
    • 47249165587 scopus 로고    scopus 로고
    • Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients
    • Lavoie S, Murray MM, Deppen P, et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 2008; 33: 2187-99.
    • (2008) Neuropsychopharmacology , vol.33 , pp. 2187-2199
    • Lavoie, S.1    Murray, M.M.2    Deppen, P.3
  • 70
    • 84857482073 scopus 로고    scopus 로고
    • Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: A double-blind, randomized, placebo-controlled trial
    • Carmeli C, Knyazeva MG, Cuenod M, et al. Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial. PloS One 2012; 7: e29341.
    • (2012) PloS One , vol.7
    • Carmeli, C.1    Knyazeva, M.G.2    Cuenod, M.3
  • 71
    • 0034671366 scopus 로고    scopus 로고
    • Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus
    • Malberg JE, Eisch AJ, Nestler EJ, et al. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000; 20: 9104-10.
    • (2000) J Neurosci , vol.20 , pp. 9104-9110
    • Malberg, J.E.1    Eisch, A.J.2    Nestler, E.J.3
  • 72
    • 0042528720 scopus 로고    scopus 로고
    • Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
    • Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003; 301: 805-9.
    • (2003) Science , vol.301 , pp. 805-809
    • Santarelli, L.1    Saxe, M.2    Gross, C.3
  • 73
    • 36349027843 scopus 로고    scopus 로고
    • Is it time to reassess the BDNF hypothesis of depression?
    • Groves JO,. Is it time to reassess the BDNF hypothesis of depression? Mol Psychiatry 2007; 12: 1079-88.
    • (2007) Mol Psychiatry , vol.12 , pp. 1079-1088
    • Groves, J.O.1
  • 74
    • 70349118076 scopus 로고    scopus 로고
    • Antidepressants increase neural progenitor cells in the human hippocampus
    • Boldrini M, Underwood MD, Hen R, et al. Antidepressants increase neural progenitor cells in the human hippocampus. Neuropsychopharmacology 2009; 34: 2376-89.
    • (2009) Neuropsychopharmacology , vol.34 , pp. 2376-2389
    • Boldrini, M.1    Underwood, M.D.2    Hen, R.3
  • 75
    • 65649125633 scopus 로고    scopus 로고
    • Neurogenesis-dependent and independent effects of fluoxetine in an animal model of anxiety/depression
    • David DJ, Samuels BA, Rainer Q, et al. Neurogenesis-dependent and independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 2009; 62: 479-93.
    • (2009) Neuron , vol.62 , pp. 479-493
    • David, D.J.1    Samuels, B.A.2    Rainer, Q.3
  • 76
    • 0034907671 scopus 로고    scopus 로고
    • BDNF mRNA expression in rat hippocampus and prefrontal cortex: Effects of neonatal ventral hippocampal damage and antipsychotic drugs
    • Lipska BK, Khaing ZZ, Weickert CS, et al. BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs. Eur J Neurosci 2001; 14: 135-44.
    • (2001) Eur J Neurosci , vol.14 , pp. 135-144
    • Lipska, B.K.1    Khaing, Z.Z.2    Weickert, C.S.3
  • 77
    • 32044441209 scopus 로고    scopus 로고
    • Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus
    • Pillai A, Terry A, Mahadik S,. Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr Res 2006; 82: 95-106.
    • (2006) Schizophr Res , vol.82 , pp. 95-106
    • Pillai, A.1    Terry, A.2    Mahadik, S.3
  • 78
    • 0036839413 scopus 로고    scopus 로고
    • Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration
    • Chlan-Fourney J, Ashe P, Nylen K, et al. Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration. Brain Res 2002; 954: 11-20.
    • (2002) Brain Res , vol.954 , pp. 11-20
    • Chlan-Fourney, J.1    Ashe, P.2    Nylen, K.3
  • 79
    • 84858338665 scopus 로고    scopus 로고
    • BDNF Val66Met impairs fluoxetine-induced enhancement of adult hippocampus plasticity
    • Bath KG, Jing DQ, Dincheva I, et al. BDNF Val66Met impairs fluoxetine-induced enhancement of adult hippocampus plasticity. Neuropsychopharmacology 2012; 37: 1297-304.
    • (2012) Neuropsychopharmacology , vol.37 , pp. 1297-1304
    • Bath, K.G.1    Jing, D.Q.2    Dincheva, I.3
  • 80
    • 77956864079 scopus 로고    scopus 로고
    • Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: Meta-analysis
    • Singh SP, Singh V, Kar N, et al. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry 2010; 197: 174-9.
    • (2010) Br J Psychiatry , vol.197 , pp. 174-179
    • Singh, S.P.1    Singh, V.2    Kar, N.3
  • 81
    • 0028914983 scopus 로고
    • A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia
    • Goff D, Midha K, Sarid-Segal O, et al. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology 1995; 117: 417-23.
    • (1995) Psychopharmacology , vol.117 , pp. 417-423
    • Goff, D.1    Midha, K.2    Sarid-Segal, O.3
  • 82
    • 34247494128 scopus 로고    scopus 로고
    • Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents
    • Cornblatt BA, Lencz T, Smith CW, et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry 2007; 68: 546-57.
    • (2007) J Clin Psychiatry , vol.68 , pp. 546-557
    • Cornblatt, B.A.1    Lencz, T.2    Smith, C.W.3
  • 83
  • 84
    • 76149112275 scopus 로고    scopus 로고
    • Hippocampal plasticity in response to exercise in schizophrenia
    • Pajonk FG, Wobrock T, Gruber O, et al. Hippocampal plasticity in response to exercise in schizophrenia. Arch Gen Psychiatry 2010; 67: 133-43.
    • (2010) Arch Gen Psychiatry , vol.67 , pp. 133-143
    • Pajonk, F.G.1    Wobrock, T.2    Gruber, O.3
  • 85
    • 68949188168 scopus 로고    scopus 로고
    • Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia?
    • Vinogradov S, Fisher M, Holland C, et al. Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia? Biol Psychiatry 2009; 66: 549-53.
    • (2009) Biol Psychiatry , vol.66 , pp. 549-553
    • Vinogradov, S.1    Fisher, M.2    Holland, C.3
  • 86
    • 0030915272 scopus 로고    scopus 로고
    • Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor
    • Lipton SA, Kim W-K, Choi Y-B, et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Neurobiology 1997; 94: 5923-8.
    • (1997) Neurobiology , vol.94 , pp. 5923-5928
    • Lipton, S.A.1    Kim, W.-K.2    Choi, Y.-B.3
  • 87
    • 0034666267 scopus 로고    scopus 로고
    • Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity
    • Kruman II, Culmsee C, Chan SL, et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 2000; 20: 6920-6.
    • (2000) J Neurosci , vol.20 , pp. 6920-6926
    • Kruman, I.I.1    Culmsee, C.2    Chan, S.L.3
  • 89
    • 0032527574 scopus 로고    scopus 로고
    • Schizophrenia and impaired homocysteine metabolism: A possible association
    • Susser E, Brown A, Klonowski E, et al. Schizophrenia and impaired homocysteine metabolism: a possible association. Biol Psychiatry 1998; 44: 141-3.
    • (1998) Biol Psychiatry , vol.44 , pp. 141-143
    • Susser, E.1    Brown, A.2    Klonowski, E.3
  • 90
  • 91
    • 76749133096 scopus 로고    scopus 로고
    • Influence of maternal MTHFR A1298C polymorphism on the risk in offspring of schizophrenia
    • Zhang C, Xie B, Fang Y, et al. Influence of maternal MTHFR A1298C polymorphism on the risk in offspring of schizophrenia. Brain Res 2010; 1320: 130-4.
    • (2010) Brain Res , vol.1320 , pp. 130-134
    • Zhang, C.1    Xie, B.2    Fang, Y.3
  • 92
    • 4444355660 scopus 로고    scopus 로고
    • Folate, homocysteine, and negative symptoms in schizophrenia
    • Goff DC, Bottiglieri T, Arning E, et al. Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry 2004; 161: 1705-8.
    • (2004) Am J Psychiatry , vol.161 , pp. 1705-1708
    • Goff, D.C.1    Bottiglieri, T.2    Arning, E.3
  • 93
    • 84874528259 scopus 로고    scopus 로고
    • Genetic variation throughout the folate metabolic pathway influences negative symptom severity in schizophrenia
    • Roffman JL, Brohawn DG, Nitenson AZ, et al. Genetic variation throughout the folate metabolic pathway influences negative symptom severity in schizophrenia. Schizophr Bull 2013; 39: 330-8.
    • (2013) Schizophr Bull , vol.39 , pp. 330-338
    • Roffman, J.L.1    Brohawn, D.G.2    Nitenson, A.Z.3
  • 94
    • 56249097252 scopus 로고    scopus 로고
    • MTHFR 677C - > T genotype disrupts prefrontal function in schizophrenia through an interaction with COMT 158Val - > Met
    • Roffman JL, Gollub RL, Calhoun VD, et al. MTHFR 677C - > T genotype disrupts prefrontal function in schizophrenia through an interaction with COMT 158Val - > Met. Proc Natl Acad Sci USA 2008; 105: 17573-8.
    • (2008) Proc Natl Acad Sci USA , vol.105 , pp. 17573-17578
    • Roffman, J.L.1    Gollub, R.L.2    Calhoun, V.D.3
  • 95
    • 79952316920 scopus 로고    scopus 로고
    • Folate supplementation in schizophrenia: A possible role for MTHFR genotype
    • Hill M, Shannahan K, Jasinski S, et al. Folate supplementation in schizophrenia: a possible role for MTHFR genotype. Schizophr Res 2011; 127: 41-5.
    • (2011) Schizophr Res , vol.127 , pp. 41-45
    • Hill, M.1    Shannahan, K.2    Jasinski, S.3
  • 96
    • 84878567704 scopus 로고    scopus 로고
    • A multicenter investigation of folate plus B12 supplementation in schizophrenia
    • in press
    • Roffman JL, Lamberti JS, Achtyes E, et al. A multicenter investigation of folate plus B12 supplementation in schizophrenia. Arch Gen Psychiatry (in press).
    • Arch Gen Psychiatry
    • Roffman, J.L.1    Lamberti, J.S.2    Achtyes, E.3
  • 97
    • 0036787407 scopus 로고    scopus 로고
    • Elevated homocysteine levels in young male patients with schizophrenia
    • Levine J, Stahl Z, Sela BA, et al. Elevated homocysteine levels in young male patients with schizophrenia. Am J Psychiatry 2002; 159: 1790-2.
    • (2002) Am J Psychiatry , vol.159 , pp. 1790-1792
    • Levine, J.1    Stahl, Z.2    Sela, B.A.3
  • 98
    • 0037364417 scopus 로고    scopus 로고
    • Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders
    • Mattson MP, Shea TB,. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 2003; 26: 137-46.
    • (2003) Trends Neurosci , vol.26 , pp. 137-146
    • Mattson, M.P.1    Shea, T.B.2
  • 99
    • 0035798238 scopus 로고    scopus 로고
    • The molecular biology of memory storage: A dialogue between genes and synapses
    • Kandel ER,. The molecular biology of memory storage: a dialogue between genes and synapses. Science 2001; 294: 1030-8.
    • (2001) Science , vol.294 , pp. 1030-1038
    • Kandel, E.R.1
  • 100
    • 84870606869 scopus 로고    scopus 로고
    • A system-level transcriptomic analysis of schizophrenia using postmortem brain tissue samples
    • Roussos P, Katsel P, Davis KL, et al. A system-level transcriptomic analysis of schizophrenia using postmortem brain tissue samples. Arch Gen Psychiatry 2012; 69: 1205-13.
    • (2012) Arch Gen Psychiatry , vol.69 , pp. 1205-1213
    • Roussos, P.1    Katsel, P.2    Davis, K.L.3
  • 101
    • 3142661662 scopus 로고    scopus 로고
    • Animal models of working memory: Insights for targeting cognitive dysfunction in schizophrenia
    • Castner SA, Goldman-Rakic PS, Williams GV,. Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia. Psychopharmacology 2004; 174: 111-25.
    • (2004) Psychopharmacology , vol.174 , pp. 111-125
    • Castner, S.A.1    Goldman-Rakic, P.S.2    Williams, G.V.3
  • 102
    • 21844469260 scopus 로고    scopus 로고
    • Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers
    • Barch DM, Carter CS,. Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr Res 2005; 77: 43-58.
    • (2005) Schizophr Res , vol.77 , pp. 43-58
    • Barch, D.M.1    Carter, C.S.2
  • 103
    • 34247387212 scopus 로고    scopus 로고
    • Tolcapone improves cognition and cortical information processing in normal human subjects
    • Apud JA, Mattay V, Chen J, et al. Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology 2007; 32: 1011-20.
    • (2007) Neuropsychopharmacology , vol.32 , pp. 1011-1020
    • Apud, J.A.1    Mattay, V.2    Chen, J.3
  • 104
    • 34249319444 scopus 로고    scopus 로고
    • A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia
    • George MS, Molnar CE, Grenesko EL, et al. A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia. Schizophr Res 2007; 93: 42-50.
    • (2007) Schizophr Res , vol.93 , pp. 42-50
    • George, M.S.1    Molnar, C.E.2    Grenesko, E.L.3
  • 105
    • 0025952455 scopus 로고
    • Recent advances in the phencyclidine model of schizophrenia
    • Javitt D, Zukin S,. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301-8.
    • (1991) Am J Psychiatry , vol.148 , pp. 1301-1308
    • Javitt, D.1    Zukin, S.2
  • 106
    • 0028323167 scopus 로고
    • Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses
    • Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199-214.
    • (1994) Arch Gen Psychiatry , vol.51 , pp. 199-214
    • Krystal, J.H.1    Karper, L.P.2    Seibyl, J.P.3
  • 107
    • 9244243064 scopus 로고    scopus 로고
    • Glutamatergic drugs for schizophrenia: A systematic review and meta-analysis
    • Tuominen HJ, Tiihonen J, Wahlbeck K,. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 2005; 72: 225-34.
    • (2005) Schizophr Res , vol.72 , pp. 225-234
    • Tuominen, H.J.1    Tiihonen, J.2    Wahlbeck, K.3
  • 108
    • 35748969317 scopus 로고    scopus 로고
    • The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments
    • Buchanan RW, Javitt DC, Marder SR, et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007; 164: 1593-602.
    • (2007) Am J Psychiatry , vol.164 , pp. 1593-1602
    • Buchanan, R.W.1    Javitt, D.C.2    Marder, S.R.3
  • 110
    • 0033557737 scopus 로고    scopus 로고
    • A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia
    • Goff D, Henderson D, Evins A, et al. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry 1999; 45: 512-4.
    • (1999) Biol Psychiatry , vol.45 , pp. 512-514
    • Goff, D.1    Henderson, D.2    Evins, A.3
  • 111
    • 0029853426 scopus 로고    scopus 로고
    • D-cycloserine added to clozapine for patients with schizophrenia
    • Goff DC, Tsai G, Manoach DS, et al. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 1996; 153: 1628-30.
    • (1996) Am J Psychiatry , vol.153 , pp. 1628-1630
    • Goff, D.C.1    Tsai, G.2    Manoach, D.S.3
  • 112
    • 1542617755 scopus 로고    scopus 로고
    • Glycine transporter i inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia
    • Tsai G, Lane HY, Yang P, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004; 55: 452-6.
    • (2004) Biol Psychiatry , vol.55 , pp. 452-456
    • Tsai, G.1    Lane, H.Y.2    Yang, P.3
  • 113
    • 77955056793 scopus 로고    scopus 로고
    • High dose D-serine in the treatment of schizophrenia
    • Kantrowitz JT, Malhotra D, Cornblatt B, et al. High dose D-serine in the treatment of schizophrenia. Schizophr Res 2010; 121: 125-30.
    • (2010) Schizophr Res , vol.121 , pp. 125-130
    • Kantrowitz, J.T.1    Malhotra, D.2    Cornblatt, B.3
  • 114
    • 0034898096 scopus 로고    scopus 로고
    • Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine
    • Sheinin A, Shavit S, Benveniste M,. Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine. Neuropharmacology 2001; 41: 151-8.
    • (2001) Neuropharmacology , vol.41 , pp. 151-158
    • Sheinin, A.1    Shavit, S.2    Benveniste, M.3
  • 115
    • 84866703056 scopus 로고    scopus 로고
    • D-cycloserine: An evolving role in learning and neuroplasticity in schizophrenia
    • Goff DC,. D-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia. Schizophr Bull 2012; 38: 936-41.
    • (2012) Schizophr Bull , vol.38 , pp. 936-941
    • Goff, D.C.1
  • 116
    • 79955474438 scopus 로고    scopus 로고
    • Behavioral analysis of NR2C knockout mouse reveals deficit in acquisition of conditioned fear and working memory
    • Hillman BG, Gupta SC, Stairs DJ, et al. Behavioral analysis of NR2C knockout mouse reveals deficit in acquisition of conditioned fear and working memory. Neurobiol Learn Mem 2011; 95: 404-14.
    • (2011) Neurobiol Learn Mem , vol.95 , pp. 404-414
    • Hillman, B.G.1    Gupta, S.C.2    Stairs, D.J.3
  • 117
    • 77953604398 scopus 로고    scopus 로고
    • Inhibition of NMDARs in the nucleus reticularis of the thalamus produces delta frequency bursting
    • Zhang Y, Llinas RR, Lisman JE,. Inhibition of NMDARs in the nucleus reticularis of the thalamus produces delta frequency bursting. Front Neural Circuits 2009; 3: 20.
    • (2009) Front Neural Circuits , vol.3 , pp. 20
    • Zhang, Y.1    Llinas, R.R.2    Lisman, J.E.3
  • 118
    • 16844387460 scopus 로고    scopus 로고
    • Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats
    • Parnas AS, Weber M, Richardson R,. Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats. Neurobiol Learn Mem 2005; 83: 224-31.
    • (2005) Neurobiol Learn Mem , vol.83 , pp. 224-231
    • Parnas, A.S.1    Weber, M.2    Richardson, R.3
  • 119
    • 56049099989 scopus 로고    scopus 로고
    • Once-weekly d-cycloserine effects on negative symptoms and cognition in schizophrenia: An exploratory study
    • Goff DC, Cather C, Gottlieb JD, et al. Once-weekly d-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr Res 2008; 106: 320-7.
    • (2008) Schizophr Res , vol.106 , pp. 320-327
    • Goff, D.C.1    Cather, C.2    Gottlieb, J.D.3
  • 120
    • 80051781845 scopus 로고    scopus 로고
    • D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia
    • Gottlieb JD, Cather C, Shanahan M, et al. D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia. Schizophr Res 2011; 131: 69-74.
    • (2011) Schizophr Res , vol.131 , pp. 69-74
    • Gottlieb, J.D.1    Cather, C.2    Shanahan, M.3
  • 121
    • 44349151445 scopus 로고    scopus 로고
    • A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy
    • Norberg MM, Krystal JH, Tolin DF,. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry 2008; 63: 1118-26.
    • (2008) Biol Psychiatry , vol.63 , pp. 1118-1126
    • Norberg, M.M.1    Krystal, J.H.2    Tolin, D.F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.